Fatalities associated with the use of γ-hydroxybutyrate and its analogues in Australasia

Medical Journal of Australia, 2004; 181(6):310-313

This article is available from the Medical Journal of Australia at:

PERMISSIONS

This document has been archived with permission from the editor of the Medical Journal of Australia, 26 April 2007.

http://hdl.handle.net/2440/10637
G

amma-hydroxybutyrate (GHB) is an endogenous water-soluble tetra-carbon neurotransmitter. It was first synthesised in 1961 and used to model GABAergic pathways in the brain. As the metabolically active end-product of a family of recreational substances, including γ-butyrolactone and 1,4-butanediol, it was first used illicitly in the late 1980s and early 1990s.

GHB was initially marketed as a health food supplement, ostensibly as a sleep aid and body-building supplement. Because it occurs naturally in the body, GHB has been considered erroneously as a “safe” natural food supplement, and its analogues have been used as recreational substances, including γ-butyrolactone and 1,4-butanediol.

 Concerns about its adverse effects were first expressed in the United States, and were given high profile with the erroneous association with the death of the actor River Phoenix in 1993. Warnings regarding the potential harm associated with its use were first issued by the Food and Drug Administration in 1990, but since then its illicit use has not only continued but increased considerably. Between 1994 and 2001, US emergency departments reported that attendances of people who had used GHB increased nearly sixfold, while deaths in people taking GHB are well documented in the international medical literature. We report here the first case series from Australia and New Zealand of fatalities associated with GHB and its analogues, and review some of the problems with the recreational use of this family of drugs.

METHODS
Deaths associated with GHB were identified from four sources:
• The database of coronial reports at Monash University National Centre for Coronial Information.

ABSTRACT
Objective: To identify deaths in Australasia associated with overdose of γ-hydroxybutyrate (GHB) and its precursors (γ-butyrolactone and 1,4-butanediol).

Design: A retrospective search of medical and scientific information sources, as well as popular newprint, for the period January 2000 – August 2003, with formal clinical, toxicological and forensic evaluation of retrieved data.

Main outcome measure: Death associated with forensic data implicating GHB or its analogues.

Results: Ten confirmed GHB-associated deaths were identified, with eight considered to be directly attributable to GHB. Only two of these eight cases were positive for ethanol toxicology.

Conclusions: Our study supports the existing evidence that GHB overdose is associated with fatalities, and that fatal overdoses occur in the context of isolated use.

Ethical considerations were discussed with the South Australian State Pathology Service, and ethical approval was obtained from the Royal Adelaide Hospital Ethics Committee.

RESULTS
For the search period 1 January 2000 to 31 August 2003, 10 deaths confirmed to be associated with GHB were identified: four through the National Centre for Coronial Information, one through personal knowledge, and the remainder through individual state forensic laboratories. Two deaths reported in the popular press as being associated with GHB were also investigated, but postmortem analysis revealed no evidence to substantiate the suggestion that GHB or its analogues were involved. Details of the 10 cases are summarised in Box 1.

The average age at death was 33.1 years (median, 28.75 years; range, 22–42 years), and eight of the 10 were men.

From the review of the records of all the deaths, eight were considered to be directly attributable to GHB, while GHB was thought to be incidental in one, and possibly contributory in the remaining death. One of the deceased suffered from mild asthma, but there were no other comorbid findings or postmortem pathological findings, apart from those described in Box 1. The two cases in which death could not be directly attributed to GHB had correspondingly lower GHB blood levels. Of the other
eight, GHB blood levels ranged from 77 mg/L to 370 mg/L (mean, 231 mg/L). Only two of these eight cases were positive for ethanol toxicology.

**DISCUSSION**

Our study supports existing evidence that GHB overdose is associated with fatalities, and that death can occur when GHB is the only substance taken.

There are a number of limitations inherent in our study. Case identification depends on suspicion being raised of GHB involvement in a death, and we have only included cases in which positive toxicological findings were reported. Analysis of tissue for the presence or absence of GHB and its analogues has traditionally not been part of the toxicological work-up for autopsy, although this is changing. In the most recent series, which was reported from Holland,6 analysis for GHB was only done in response to specific information or requests, as it is not part of routine testing in hospitals and forensic institutes. It is possible that deaths caused by GHB and its analogues have been overlooked because evidence of GHB in tissue had not been specifically sought.

There are many countries in the South-East Asia and Oceania regions where the facilities for analysis of GHB do not exist. Furthermore, GHB is metabolised very quickly — after ingestion of 1–3 g, GHB can only be detected for 8 hours in blood and 12 hours in urine.7-9 This makes it difficult to trace if not anticipated and actively pursued. In all probability, the number of deaths reported in this series is an underestimate of actual deaths over the same period.

It has been reported that GHB levels can increase after death, and concern exists that this might be used to confound forensic investigations.10 However, tissue levels between those endogenously produced and those found in significant overdose appear to be at least an order of magnitude different. GHB levels in overdose have been well.
Banned in many countries, 16 but, with a mean postmortem level of 112.3 mg/L, this compares with the contributory cause of death being 231 mg/L, with a range of 77–370 mg/L. This compares with other mean postmortem levels of 112.3 mg/L, and isolated GHB overdose levels of 345 mg/L.12

The levels found in our patients were very high, even compared with levels of GHB reported in other cases in the medical literature. This may support the hypothesis that there is little understanding of the potential hazards of this drug by the community that uses it, a fact reflected in its continuing popularity among young Australians.13

As all deaths occur in the prehospital setting. This may support the hypothesis that there is little understanding of the potential hazards of this drug by the community that uses it, a fact reflected in its continuing popularity among young Australians.13

The precursor chemicals, γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD), have been marketed to bypass the current near-universal ban on GHB, but have been shown to be equally dangerous.14 GBL has been banned in many countries,16 but, with a multimillion-dollar value in trade on the international industrial chemical market, their universal ban on GHB, but have been shown to be equally dangerous.14,15 GBL has been banned in many countries,16 but, with a multimillion-dollar value in trade on the international industrial chemical market, legislation to control the distribution of 1,4-BD is proving more problematic. Both GBL and 1,4-BD are endogenously converted by the body into GHB by peripheral lactonases,14,15 respectively. In a case published elsewhere,15 1,4-BD was not identified in postmortem tissue, but analysis of samples from the scene was highly suggestive of 1,4-BD being the cause of death. Because of the restrictions in obtaining GHB, it is probable that most of the “GHB” being consumed in Australia is now in the form of GBL or 1,4-BD.

GHB and GHB-like drugs are taken to induce a euphoric feeling, an effect that occurs at a dose much lower than that required to induce unconsciousness. In an Australian series of 76 GHB users,17 half had experienced a GHB overdose in which they had lost consciousness. More worryingly, some of these users did not see loss of consciousness as a negative outcome, many reporting that they had received reassurance from the Internet that “GHB overdose was not in itself a dangerous thing”. The information provided by such sources is notoriously unreliable18 and partisan towards drug use. Those who had overdosed felt that over 90% of other users of GHB were similarly likely to overdose at some stage.19

As might be expected for an unregulated, illicitly produced and covertly distributed substance, it is difficult to estimate the incidence of GHB use in Australia. Press reporting aside,20,21 most indicators suggest that its use is increasing. The Australian Customs Service reported 39 detections between 1 January and 16 April 2002 — more than in the previous 4 years combined.22 Further information regarding trends in use can be obtained from the Illicit Drug Reporting System. In 2000, less than 1% of party drug users interviewed reported ever having used GHB; this proportion increased to 23% in 2001 and 35% in 2002. Similarly, reports of recent use increased relative to previous years.23

As all deaths occur in the prehospital setting, it is unlikely that any measures other than those involving harm reduction will have a significant impact on deaths from this group of drugs.

### ACKNOWLEDGEMENTS

This study would not have been possible without the invaluable assistance of Kristen Murray, Project Manager, Monash University National Centre for Coronial Information, and the toxicology principals: Dennis Pianca (ACT), Tanya Prolov (NSW), Olaf Drummer (VIC), Kathryn Campbell (TAS), Neville Bailey (QLD/NT), Robert Hanssen (WA), Stuart Dickson (NZ). We would also like to thank Dr Christian Hamilton-Craig for drawing our attention to one of the deaths in NSW.

### COMPETING INTERESTS

None identified.
REFERENCES


(Received 27 Feb 2004, accepted 30 Jul 2004)